SNGX vs ADXN

Addex Therapeutics Ltd (ADXN) offers the better valuation at 0.

7x trailing P/E, making it the more compelling value choice. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Addex Therapeutics Ltd (ADXN) delivered a total return of -96.

5%, compared to -99. 9% for Soligenix, Inc. (SNGX). Over 10 years, the gap is even starker: ADXN returned -96. 9% versus SNGX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Addex Therapeutics Ltd (ADXN) is the lower-risk stock at 0.

59β versus Soligenix, Inc. 's 1. 97β — meaning SNGX is approximately 233% more volatile than ADXN relative to the S&P 500. On balance sheet safety, Addex Therapeutics Ltd (ADXN) carries a lower debt/equity ratio of 0% versus 36% for Soligenix, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Addex Therapeutics Ltd grew EPS 150.

0% year-over-year, compared to 60. 7% for Soligenix, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Addex Therapeutics Ltd (ADXN) is the more profitable company, earning 1746% net margin versus 0.

0% for Soligenix, Inc. — meaning it keeps 1746% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SNGX leads at 0. 0% versus -681. 8% for ADXN. At the gross margin level — before operating expenses — ADXN leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Addex Therapeutics Ltd (ADXN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

59)). Soligenix, Inc. (SNGX) carries a higher beta of 1. 97 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ADXN: -96. 9%, SNGX: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SNGX is a small-cap quality compounder stock; ADXN is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.